Europe – European Commission approves cystic fibrosis treatment for six to 11-year-olds

There is currently no cure for cystic fibrosis (CF), a debilitating, progressive condition with over 10,830 people in the UK currently diagnosed with the disease.

The European Commission (EC) has granted approval for the label extension of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with ivacaftor.

This has been recommended for the treatment of CF in patients aged six to 11-years-old who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene…